NXL vs. MDAI, EDAP, CTCX, PYPD, DXR, PSTV, SRTS, ZYXI, APT, and GUTS
Should you be buying Nexalin Technology stock or one of its competitors? The main competitors of Nexalin Technology include Spectral AI (MDAI), EDAP TMS (EDAP), Carmell (CTCX), PolyPid (PYPD), Daxor (DXR), Plus Therapeutics (PSTV), Sensus Healthcare (SRTS), Zynex (ZYXI), Alpha Pro Tech (APT), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry.
Nexalin Technology vs. Its Competitors
Nexalin Technology (NASDAQ:NXL) and Spectral AI (NASDAQ:MDAI) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by insiders. Comparatively, 30.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Nexalin Technology and Nexalin Technology both had 1 articles in the media. Spectral AI's average media sentiment score of 1.88 beat Nexalin Technology's score of 1.03 indicating that Spectral AI is being referred to more favorably in the news media.
Nexalin Technology has higher earnings, but lower revenue than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Nexalin Technology currently has a consensus target price of $5.00, suggesting a potential upside of 422.85%. Spectral AI has a consensus target price of $3.50, suggesting a potential upside of 81.35%. Given Nexalin Technology's higher probable upside, equities analysts clearly believe Nexalin Technology is more favorable than Spectral AI.
Spectral AI has a net margin of -51.97% compared to Nexalin Technology's net margin of -5,057.14%. Spectral AI's return on equity of 0.00% beat Nexalin Technology's return on equity.
Nexalin Technology has a beta of 3.68, suggesting that its stock price is 268% more volatile than the S&P 500. Comparatively, Spectral AI has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Summary
Spectral AI beats Nexalin Technology on 8 of the 13 factors compared between the two stocks.
Get Nexalin Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nexalin Technology Competitors List
Related Companies and Tools
This page (NASDAQ:NXL) was last updated on 9/1/2025 by MarketBeat.com Staff
Free NXL Stock Alerts